Pharmaceuticals - Community Register

  

Community register of medicinal products for human use


AUTHORISED  

Product information

Invented name: Tafinlar   
Auth. number : EU/1/13/865
Active substance : DABRAFENIB
ATC: Anatomical main group: L - Antineoplastic and immunomodulating agents
Therapeutic subgroup: L01 - Cytostatics
Pharmacological subgroup: L01X - Other cytostatics
Chemical subgroup: L01XE - Protein kinase inhibitors
Chemical substance: L01XE23 - Dabrafenib
(See WHO ATC Index)
Indication: Monotherapy for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
Marketing Authorisation Holder: Novartis Europharm Limited
Frimley Business Park, Camberley GU16 7SR, United Kingdom
EPAR and active package presentations

Package presentations

Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register.

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
29/08/2013 Centralised - Authorisation EMEA/H/C/2604 (2013)5604 of 26/08/2013
20/02/2014 Centralised - Variation EMEA/H/C/2604/II/2/G
Updated with Decision(2014)9043 of 21/11/2014
05/06/2014 Centralised - Variation EMEA/H/C/2604/IG/442
Updated with Decision(2014)9043 of 21/11/2014
24/07/2014 Centralised - Variation EMEA/H/C/2604/II/1/G
Updated with Decision(2014)9043 of 21/11/2014
25/11/2014 PSUSA - Modification EMEA/H/C/2604/PSUV/5 (2014)9043 of 21/11/2014
22/01/2015 Centralised - Variation EMEA/H/C/2604/II/6
Updated with Decision(2015)3220 of 06/05/2015
08/05/2015 Centralised - Transfer Marketing Authorisation Holder (2015)3220 of 06/05/2015
11/06/2015 Centralised - Variation EMEA/H/C/2604/II/0008